In the PARAGON-HF trial of angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction, subgroup analysis suggested participants with a lower left ventricular ejection fraction may derive benefit from the intervention. The gene discussed is MME; the disease is hydrops fetalis.